Nanobiotix S.A. (NBTX) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Nanobiotix S.A.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Manufacturing
Prev close 35.40 · gapped above the open, then crossed back over prior close. High/low 36.31 at 10:15 am ET, 35.39 at 4:00 pm ET.
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
No case yet. It builds on the next filing, report or 13F period.
No peer readings for Nanobiotix S.A. yet.
19 managers report a position worth $218.4M between them, and 1 of them hold 80% of it.
tall tick = annual report · 1 on record
NBTX (Nanobiotix S.A.) has 2 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: JNJ +0.25%, in healthcare.